Drug Sales Trends for DIOVAN

Payment Methods and Pharmacy Types for DIOVAN (2020)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$15,194,882
INSIDE HMO/CLINIC/HOSPITAL	$2,051,150

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	33,198
INSIDE HMO/CLINIC/HOSPITAL	3,431

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$26,659,509
SELF OR FAMILY	$366,296

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for DIOVAN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
DIOVAN			2022
DIOVAN			2021
DIOVAN			2020
DIOVAN			2019
DIOVAN			2018
DIOVAN			2017

DIOVAN (VALSARTAN) MARKET ANALYSIS AND SALES PROJECTIONS

Last updated: August 31, 2026

Diovan, Novartis’ brand of valsartan, is a mature antihypertensive with limited standalone brand value after loss of major patent protection in the United States and Europe. Novartis’ historical Diovan franchise generated more than $6 billion annually at its peak, but sales declined sharply after generic entry. The commercial opportunity has shifted from branded Diovan to generic valsartan, fixed-dose combinations, and newer cardiovascular products such as Entresto.

A base-case market model estimates global valsartan product sales of approximately $1.4 billion in 2024, rising to $1.6 billion by 2030. Standalone branded Diovan sales are estimated at less than $50 million annually and are likely to continue declining. Generic valsartan, combination products, and institutional tenders account for most current market value.

What is Diovan and how large is its target market?

Diovan is the trade name for valsartan, an angiotensin II receptor blocker, or ARB. It is approved for hypertension, heart failure, and reduction of cardiovascular mortality following myocardial infarction in specified patients. The product is administered as tablets, with approved strengths generally ranging from 40 mg to 320 mg depending on the indication and market.

Diovan product profile

Attribute	Details
Active ingredient	Valsartan
Drug class	Angiotensin II receptor blocker
Original company	Novartis
U.S. approval	1996
Main indications	Hypertension, heart failure, post-myocardial infarction
Dosage forms	Immediate-release tablets; fixed-dose combinations
Key combinations	Valsartan/hydrochlorothiazide; amlodipine/valsartan
Reference product	Diovan
U.S. regulatory status	Generic competition established
Current commercial position	Mature, largely genericized product

Valsartan competes with losartan, irbesartan, candesartan, telmisartan, olmesartan, ACE inhibitors, calcium-channel blockers, thiazide diuretics, and combination therapies. Prescribing is increasingly determined by generic price, payer formulary position, clinical familiarity, and availability rather than brand differentiation.

How much did Diovan sales generate historically?

Diovan was one of Novartis’ largest products before patent expiry. Peak annual sales exceeded $6 billion, supported by broad hypertension use and later expansion into heart failure and post-myocardial infarction treatment.

Year	Approximate Diovan sales	Commercial development
2008	$5.7 billion	Mature global brand
2009	$6.0 billion	Near peak sales
2010	$6.1 billion	Peak-period performance
2011	$6.0 billion	Generic-entry preparation
2012	$4.7 billion	U.S. generic competition
2013	$3.2 billion	Accelerated erosion
2014	Approximately $2 billion	Broad generic substitution
2024	Less than $50 million estimated branded sales	Residual brand and selected markets

Novartis reported Diovan sales of approximately $6 billion around the peak period, followed by a steep decline after loss of exclusivity and generic launches.[1] The historical sales curve reflects the standard lifecycle of an oral small-molecule cardiovascular product: rapid uptake, expansion through additional indications, high-margin maturity, and abrupt price erosion after patent expiry.

When did Diovan lose exclusivity?

Diovan lost practical market exclusivity in the United States in 2012. The core U.S. patent, U.S. Patent No. 5,399,578, covered valsartan-related compounds and had an expiry date in the 2012 period, subject to patent-term calculations and pediatric exclusivity.[2]

Key exclusivity milestones

Event	Approximate date	Effect
U.S. approval	1996	Launch of Diovan
Core compound patent protection	Through 2012	Protected valsartan monotherapy
U.S. generic entry	2012	Rapid price and volume erosion
European patent expiry	2011-2012 period	Broad European generic entry
Combination-product erosion	2012 onward	Decline in Diovan HCT and related products
Current status	Genericized	Limited standalone brand protection

Patent expiry did not eliminate every form of intellectual property immediately. Formulation, combination, process, and method-of-use patents may have had different expiry dates and enforceability. Those rights did not preserve substantial exclusivity for the standalone Diovan franchise.

What patents protect Diovan and valsartan products?

The principal historical protection was the valsartan compound patent. Later patent activity covered specific formulations, combinations, manufacturing processes, and therapeutic uses.

Core patent estate

Patent or right	Subject matter	Commercial relevance
U.S. Patent No. 5,399,578	Valsartan and related substituted heterocyclic compounds	Principal compound protection
Diovan regulatory exclusivity	FDA-approved reference-product exclusivity	Expired
Valsartan/HCT patents	Fixed-dose combination of valsartan and hydrochlorothiazide	Protected combination products for limited periods
Amlodipine/valsartan patents	Fixed-dose combination marketed as Exforge	Separate product estate
Process patents	Manufacturing and purification methods	Potential manufacturing barriers, generally limited after broad generic access
Method-of-use patents	Hypertension, heart failure, and cardiovascular-risk uses	Narrower protection and subject to label carve-outs

Patent protection for a mature small-molecule product should be analyzed by product configuration rather than by brand name alone. Diovan monotherapy, Diovan HCT, and amlodipine/valsartan had separate regulatory and patent histories.

What is the Orange Book status of Diovan?

The U.S. Food and Drug Administration’s Orange Book historically listed Diovan and related valsartan products as reference-listed drugs. The commercial significance of those listings declined after expiration of the principal patents and approval of multiple abbreviated new drug applications.

Generic valsartan manufacturers typically relied on ANDA certifications, including Paragraph III or Paragraph IV certifications depending on the status of listed patents. Once the core patents expired and generic products launched, the Orange Book ceased to provide a meaningful barrier to ordinary valsartan tablets.

The current commercial question is no longer whether generic valsartan can enter the market. It is whether a manufacturer can achieve sufficient scale, supply reliability, and reimbursement access to earn acceptable margins.

Which companies challenged Diovan patents?

Generic manufacturers, including major U.S., European, Indian, and Israeli pharmaceutical companies, pursued valsartan entry as patent protection approached expiry. Companies active in generic ARB products have included Teva, Mylan, Sandoz, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Zydus, Lupin, and other regional suppliers.

Paragraph IV activity was commercially important before 2012 because an early successful challenge could accelerate entry. After expiry, competition shifted toward ANDA approvals, manufacturing capacity, tender access, and price.

Generic-entry dynamics

1. Generic applicants targeted the compound patent and relevant listed combination patents.
2. Patent challenges created potential 180-day first-filer advantages under the Hatch-Waxman framework.
3. Multiple manufacturers entered after the main patent barrier expired.
4. Prices declined as additional suppliers obtained approval.
5. Pharmacy substitution shifted volume away from Diovan.

What litigation and settlements affected Diovan?

Diovan’s major litigation exposure centered on generic challenges to Novartis’ core valsartan patents and related product rights. The economically important resolution was the transition from protected brand sales to generic competition around 2012.

The Diovan case differs from products with active patent settlements that delay generic entry for many years. Valsartan became a broad generic market relatively soon after core exclusivity ended. Current litigation risk is more likely to involve manufacturing, supply, product liability, recalls, or regulatory compliance than an attempt to restore monopoly pricing.

The 2018 discovery of nitrosamine contamination in certain valsartan products led to global recalls and regulatory investigations. The issue affected multiple manufacturers and exposed supply-chain vulnerabilities involving active pharmaceutical ingredients sourced from selected production facilities.[3] It did not restore Diovan’s brand exclusivity.

What is the current competitive landscape for valsartan?

Valsartan competes in a high-volume, low-price therapeutic category. Generic substitution is widespread in the United States and Europe. In emerging markets, branded generics retain more pricing power, but local competition remains substantial.

Main competitive products

Product	Active ingredient or combination	Competitive position
Diovan	Valsartan	Reference brand with limited residual sales
Generic valsartan	Valsartan	Primary volume product
Co-Diovan and generic equivalents	Valsartan/hydrochlorothiazide	Established combination market
Exforge and generic equivalents	Amlodipine/valsartan	Higher-value combination segment
Losartan	Losartan	Large ARB competitor
Atacand	Candesartan	Heart-failure and hypertension competitor
Avapro	Irbesartan	Mature ARB competitor
Micardis	Telmisartan	Long-acting ARB competitor
Entresto	Sacubitril/valsartan	Higher-value heart-failure product, not a direct generic Diovan substitute

Entresto is strategically important because it uses valsartan as one component but has a different mechanism, clinical positioning, and patent estate. It has largely replaced Diovan as Novartis’ major cardiovascular growth product. Entresto’s sales should not be counted as Diovan or generic valsartan revenue.

What are the sales projections for Diovan and valsartan?

The following model separates residual branded Diovan revenue from the broader valsartan product market. The forecast assumes continued generic substitution, low inflation-adjusted pricing, stable global hypertension prevalence, and modest growth in fixed-dose combinations.

Global sales projection

Year	Branded Diovan	Generic standalone valsartan	Valsartan combinations	Total valsartan product market
2024A	$35 million	$850 million	$515 million	$1.40 billion
2025E	$30 million	$870 million	$535 million	$1.44 billion
2026E	$26 million	$890 million	$555 million	$1.47 billion
2027E	$22 million	$910 million	$575 million	$1.51 billion
2028E	$19 million	$925 million	$595 million	$1.54 billion
2029E	$16 million	$940 million	$615 million	$1.57 billion
2030E	$14 million	$950 million	$640 million	$1.60 billion

The model implies approximately 2.2% compound annual growth for the total valsartan product market from 2024 to 2030. Branded Diovan declines at approximately 14% annually as residual prescriptions migrate to generic equivalents.

Scenario analysis

Scenario	2030 total valsartan sales	Main assumptions
Downside	$1.25 billion	Accelerated price erosion, reduced branded-generic use, tender compression
Base case	$1.60 billion	Stable volume, modest combination growth, low price inflation
Upside	$1.95 billion	Higher diagnosis rates, stronger emerging-market demand, combination-product expansion

The upside case does not depend on a return of Diovan brand pricing. It depends on volume growth and higher-value combination products.

What generic-entry risks exist for Diovan?

Generic entry is already established, so the risk is commercial erosion rather than future launch disruption. The main risks are:

• Continued pharmacy substitution away from branded Diovan.
• Price compression from additional suppliers.
• Tender concentration among a small number of low-cost manufacturers.
• Reimbursement exclusion of the Novartis brand.
• Product recalls caused by active pharmaceutical ingredient contamination.
• Supply interruptions that shift volume temporarily between manufacturers.
• Reduced physician differentiation for standalone valsartan.
• Substitution toward losartan or other ARBs.

A new generic entrant would face low regulatory novelty but meaningful operational barriers. FDA approval alone does not guarantee commercial access. Manufacturers need validated API supply, adequate batch capacity, quality-system compliance, stable distribution, and payer contracts.

How strong is the Diovan patent estate?

The standalone Diovan patent estate is weak from a present-value perspective because the core compound protection expired and generic competition is entrenched. Residual value may remain in selected jurisdictions, branded-generic markets, combination products, or manufacturing know-how.

Patent-estate category	Current strength	Commercial assessment
Core valsartan compound	Low	Expired
Standalone tablet formulation	Low	Generic substitution established
Valsartan/HCT combination	Low to moderate	Product-specific rights largely matured
Amlodipine/valsartan	Product-dependent	Separate combination market
Manufacturing processes	Moderate in narrow cases	Difficult to use as a broad market barrier
Method of use	Low to moderate	May support narrow indications, not broad monopoly
Trade secrets and supply chain	Moderate operational value	Can affect cost and reliability

Diovan’s strongest remaining defenses are regulatory quality, physician familiarity, and supply reliability. Those are commercial advantages, not meaningful patent exclusivity.

Are biosimilar risks relevant to Diovan?

No. Diovan is a chemically synthesized small-molecule drug, so biosimilar regulation does not apply. The relevant competitive pathway is the ANDA process for generic drugs under the Hatch-Waxman Act.

This distinction matters for forecasting. Generic valsartan manufacturers can rely on pharmaceutical equivalence and bioequivalence rather than conducting the type of comparative clinical development required for biosimilars. Entry costs and timelines are therefore lower than for biologic products.

What FDA regulatory issues affect valsartan sales?

The FDA approved valsartan as a conventional small-molecule prescription drug and authorized generic products through ANDAs. The most important recent regulatory event was the valsartan impurity crisis, which resulted in recalls beginning in 2018 after detection of N-nitrosodimethylamine and related impurities in some products.[3]

Regulatory controls now emphasize:

• API supplier qualification.
• Nitrosamine risk assessment.
• Process impurity controls.
• Stability testing.
• Manufacturing-site inspections.
• Recall readiness.
• Continuity of supply.

These requirements can favor larger manufacturers with diversified sourcing and stronger quality systems. They can also create temporary price increases when suppliers exit or products are recalled.

What licensing deals affect Diovan?

Diovan’s original commercialization was controlled by Novartis, with regional distribution and generic licensing arrangements varying by market. The most commercially important licensing activity now concerns generic valsartan supply, authorized generics, local manufacturing, and fixed-dose combinations.

The product does not have a current licensing profile comparable with newer specialty drugs. Licensing value is concentrated in:

• Regional registration rights.
• Local manufacturing arrangements.
• Hospital and government tenders.
• Authorized-generic supply.
• Combination-product commercialization.
• API and finished-dose supply contracts.

The strategic value of Diovan-related licensing is therefore volume access rather than patent-based royalty economics.

How does Diovan compare with Entresto?

Factor	Diovan	Entresto
Active components	Valsartan	Sacubitril/valsartan
Drug class	ARB	Angiotensin receptor-neprilysin inhibitor
Primary commercial use	Hypertension and selected cardiovascular indications	Heart failure
Patent position	Mature and expired	Active product-specific estate during much of the forecast period
Generic competition	Established	More limited and jurisdiction-dependent
Revenue profile	Low-value genericized	Higher-value branded cardiovascular product
Novartis strategic role	Legacy product	Major cardiovascular franchise

Entresto has materially higher revenue potential because its clinical positioning and patent protection differ from standalone valsartan. Diovan should not be treated as a proxy for Entresto’s growth trajectory.

What geographic markets offer the greatest opportunity?

The United States and Western Europe offer high prescription volume but limited branded pricing. Growth opportunities are more likely in China, India, Latin America, Southeast Asia, the Middle East, and selected African markets.

Geographic outlook

Region	Market condition	Outlook
United States	Mature, generic-dominated	Stable volume, continuing price pressure
Western Europe	Mature and tender-driven	Low growth, low pricing
Japan	Mature branded-generic market	Stable demand with local pricing controls
China	Large hypertension population	Volume growth and local competition
India	Strong branded-generic presence	Competitive growth, fragmented pricing
Latin America	Mixed generic and branded use	Moderate volume growth
Middle East	Import and tender dependent	Opportunity for reliable suppliers
Africa	Underdiagnosis and access constraints	Long-term volume potential, low near-term pricing

Emerging markets can support higher unit growth, but revenue conversion depends on reimbursement, public procurement, local registration, and distribution infrastructure.

What are the likely generic launch and investment scenarios?

For standalone Diovan, no future first generic launch event is expected in the major markets because entry already occurred. The relevant scenarios are:

1. Residual brand decline: branded Diovan falls toward a small maintenance business.
2. Generic consolidation: supply shifts toward fewer manufacturers as margins compress.
3. Combination growth: valsartan/hydrochlorothiazide and amlodipine/valsartan gain share relative to monotherapy.
4. Supply disruption: recalls or API constraints create temporary pricing and share volatility.
5. Emerging-market expansion: volume rises while average selling prices remain low.
6. Strategic substitution: physicians and payers shift heart-failure patients toward Entresto or other newer therapies.

Key Takeaways

• Diovan is a mature valsartan brand with minimal remaining standalone exclusivity.
• Historical peak sales exceeded $6 billion annually.
• Core U.S. patent protection expired in the 2012 period, enabling broad generic competition.
• Branded Diovan sales are estimated below $50 million annually.
• The broader global valsartan product market is modeled at $1.4 billion in 2024 and $1.6 billion in 2030.
• Generic valsartan and fixed-dose combinations account for nearly all current commercial value.
• Biosimilar risk is irrelevant because valsartan is a small-molecule drug.
• The main risks are price erosion, supply disruption, API quality events, and payer exclusion.
• Entresto is a separate, higher-value Novartis product and should not be included in Diovan revenue forecasts.
• Future opportunity lies in combination products, emerging markets, tenders, and reliable low-cost manufacturing.

FAQs About Diovan Sales, Patents, and Market Competition

Is Diovan still sold in the United States?

Diovan may remain available in limited branded channels, but U.S. valsartan prescriptions are overwhelmingly supplied by generic manufacturers. Brand availability does not imply meaningful brand pricing power.

What is the generic name for Diovan?

The generic name is valsartan. Generic valsartan is available in multiple tablet strengths and from numerous manufacturers.

Does Novartis still earn significant revenue from Diovan?

No. Novartis’ major cardiovascular revenue has shifted from Diovan to newer products, particularly Entresto. Diovan revenue is a small residual amount compared with its historical peak.

Can a new manufacturer still enter the valsartan market?

Yes, subject to FDA or other national regulatory approval, bioequivalence, manufacturing compliance, API qualification, and commercial distribution. The principal barriers are operational and economic rather than patent-based.

Is valsartan a good licensing opportunity?

Valsartan can support licensing opportunities in emerging markets, public tenders, authorized generics, and fixed-dose combinations. Standalone branded licensing has limited value because broad generic competition has eliminated most exclusivity-based economics.

References

1. Novartis AG. (2009-2014). Annual report. Basel, Switzerland: Author.

2. U.S. Patent and Trademark Office. (1995). U.S. Patent No. 5,399,578: N-substituted heterocyclic compounds. Washington, DC: U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2018). FDA updates and press announcements on valsartan, losartan, and irbesartan recalls. Silver Spring, MD: U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (1996). Diovan prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: U.S. Department of Health and Human Services.